Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer
Giorgio Bogani(Fondazione IRCCS Istituto Nazionale dei Tumori), Mansoor Raza Mirza(C4 Therapeutics (United States)), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Brian M. Slomovitz(Mount Sinai Medical Center), Ramez N. Eskander(University of California San Diego), Kathleen N. Moore(University of Oklahoma Medical Center), Matthew A. Powell(Washington University in St. Louis), Nicoletta Colombo(University of Milano-Bicocca), Francesco Raspagliesi(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Pilar Barretina-Ginesta(Universitat de Girona), Bradley J. Monk(Florida Cancer Specialists & Research Institute)
Cited by 123
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k